Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice

Timothy B. Campbell, Giao Hangoc, Ying Liu, Karen Pollok, Hal Broxmeyer

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

CD26, a surface serine dipeptidylpeptidase IV (DPPIV) expressed on different cell types, cleaves the amino-terminal dipeptide from some chemokines, including stromal-derived factor-1 (SDF-1/CXCL12). SDF-1/CXCL12 plays important roles in hematopoietic stem cell (HSC) homing, engraftment, and mobilization. Inhibition of CD26 peptidase activity enhances homing, engraftment, and competitive repopulation in congenic mouse bone marrow cell transplants. Our studies evaluated a role for CD26 in in vivo engraftment of HSCs from human umbilical cord blood (CB) into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Pretreating purified CD34+ human CB cells with Diprotin A, a DPPIV inhibitor, for 15 min significantly enhanced engraftment. Treatment did not affect differentiation of CD34+ cells in vivo, as measured phenotypically by human markers CD33, CD38, CD19, and CD34. We found that the percentage of CD26+ cells within the more immature cells (CD34+CD38-) was significantly higher than in the more mature population (CD34+CD38+). These results suggest that inhibition of CD26 may be one way to enhance engraftment of limiting numbers of stem cells during CB transplantation.

Original languageEnglish
Pages (from-to)347-353
Number of pages7
JournalStem Cells and Development
Volume16
Issue number3
DOIs
StatePublished - Jun 2007

Fingerprint

Severe Combined Immunodeficiency
Fetal Blood
Blood Cells
diprotin A
Cord Blood Stem Cell Transplantation
Congenic Mice
Dipeptides
Hematopoietic Stem Cells
Chemokines
Bone Marrow Cells
Serine
Cell Differentiation
Peptide Hydrolases
Transplants
Population
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. / Campbell, Timothy B.; Hangoc, Giao; Liu, Ying; Pollok, Karen; Broxmeyer, Hal.

In: Stem Cells and Development, Vol. 16, No. 3, 06.2007, p. 347-353.

Research output: Contribution to journalArticle

@article{64d007451a84467587db3f329f940cf5,
title = "Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice",
abstract = "CD26, a surface serine dipeptidylpeptidase IV (DPPIV) expressed on different cell types, cleaves the amino-terminal dipeptide from some chemokines, including stromal-derived factor-1 (SDF-1/CXCL12). SDF-1/CXCL12 plays important roles in hematopoietic stem cell (HSC) homing, engraftment, and mobilization. Inhibition of CD26 peptidase activity enhances homing, engraftment, and competitive repopulation in congenic mouse bone marrow cell transplants. Our studies evaluated a role for CD26 in in vivo engraftment of HSCs from human umbilical cord blood (CB) into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Pretreating purified CD34+ human CB cells with Diprotin A, a DPPIV inhibitor, for 15 min significantly enhanced engraftment. Treatment did not affect differentiation of CD34+ cells in vivo, as measured phenotypically by human markers CD33, CD38, CD19, and CD34. We found that the percentage of CD26+ cells within the more immature cells (CD34+CD38-) was significantly higher than in the more mature population (CD34+CD38+). These results suggest that inhibition of CD26 may be one way to enhance engraftment of limiting numbers of stem cells during CB transplantation.",
author = "Campbell, {Timothy B.} and Giao Hangoc and Ying Liu and Karen Pollok and Hal Broxmeyer",
year = "2007",
month = "6",
doi = "10.1089/scd.2007.9995",
language = "English",
volume = "16",
pages = "347--353",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice

AU - Campbell, Timothy B.

AU - Hangoc, Giao

AU - Liu, Ying

AU - Pollok, Karen

AU - Broxmeyer, Hal

PY - 2007/6

Y1 - 2007/6

N2 - CD26, a surface serine dipeptidylpeptidase IV (DPPIV) expressed on different cell types, cleaves the amino-terminal dipeptide from some chemokines, including stromal-derived factor-1 (SDF-1/CXCL12). SDF-1/CXCL12 plays important roles in hematopoietic stem cell (HSC) homing, engraftment, and mobilization. Inhibition of CD26 peptidase activity enhances homing, engraftment, and competitive repopulation in congenic mouse bone marrow cell transplants. Our studies evaluated a role for CD26 in in vivo engraftment of HSCs from human umbilical cord blood (CB) into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Pretreating purified CD34+ human CB cells with Diprotin A, a DPPIV inhibitor, for 15 min significantly enhanced engraftment. Treatment did not affect differentiation of CD34+ cells in vivo, as measured phenotypically by human markers CD33, CD38, CD19, and CD34. We found that the percentage of CD26+ cells within the more immature cells (CD34+CD38-) was significantly higher than in the more mature population (CD34+CD38+). These results suggest that inhibition of CD26 may be one way to enhance engraftment of limiting numbers of stem cells during CB transplantation.

AB - CD26, a surface serine dipeptidylpeptidase IV (DPPIV) expressed on different cell types, cleaves the amino-terminal dipeptide from some chemokines, including stromal-derived factor-1 (SDF-1/CXCL12). SDF-1/CXCL12 plays important roles in hematopoietic stem cell (HSC) homing, engraftment, and mobilization. Inhibition of CD26 peptidase activity enhances homing, engraftment, and competitive repopulation in congenic mouse bone marrow cell transplants. Our studies evaluated a role for CD26 in in vivo engraftment of HSCs from human umbilical cord blood (CB) into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Pretreating purified CD34+ human CB cells with Diprotin A, a DPPIV inhibitor, for 15 min significantly enhanced engraftment. Treatment did not affect differentiation of CD34+ cells in vivo, as measured phenotypically by human markers CD33, CD38, CD19, and CD34. We found that the percentage of CD26+ cells within the more immature cells (CD34+CD38-) was significantly higher than in the more mature population (CD34+CD38+). These results suggest that inhibition of CD26 may be one way to enhance engraftment of limiting numbers of stem cells during CB transplantation.

UR - http://www.scopus.com/inward/record.url?scp=34347366261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347366261&partnerID=8YFLogxK

U2 - 10.1089/scd.2007.9995

DO - 10.1089/scd.2007.9995

M3 - Article

C2 - 17610364

AN - SCOPUS:34347366261

VL - 16

SP - 347

EP - 353

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 3

ER -